Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
News|Articles|November 30, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-12-02-2015
- Volume 11
- Issue 12
Instrument Measures Endotoxins at Point of Use
Author(s)Pharmaceutical Technology Editors
Charles River offers the Endosafe nexgen-PTS endotoxin testing system.
The Endosafe nexgen-PTS from Charles River is a point-of-use, handl-held spectrometer that uses disposable cartridges designed to provide real-time endotoxin testing. Quantitative LAL test results are available in 15 minutes, the company reports.
The unit provides endotoxin measurement, acceptance criteria and sample reaction data on a screen in real time. A touch screen LCD display can be use while wearing gloves. Features include automated barcode scanning; user management with three levels of user profiles and password protection; and Wi-Fi connectivity for remote printing. The nexgen-PTS combines Charles River’s FDA-licensed cartridges and USP/BET-compliant test, allowing for administration control.
Source:
Articles in this issue
almost 11 years ago
Software Corrects Spectra Dataalmost 11 years ago
Lab Reactor Designed for Scale-upalmost 11 years ago
Instrument Manufacturers Collaborate on Interoperabilityalmost 11 years ago
HTS Reader Features Three Light Sourcesalmost 11 years ago
“A Hit for Every Target” and Changing the Model for Pharma Innovationalmost 11 years ago
Researchers Identify Advances for Heterocyclic Chemistryalmost 11 years ago
CMOs Lead Ongoing Drive for Single-Use Adoptionalmost 11 years ago
System Automates Traceabilityalmost 11 years ago
Lufthansa Cargo Offers CSafe ContainersRelated to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
3
PharmTech’s Weekly Roundup—September 25, 2026
4
PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP
5